000292356 001__ 292356
000292356 005__ 20250820121913.0
000292356 0247_ $$2doi$$a10.1016/j.bjps.2024.05.043
000292356 0247_ $$2pmid$$apmid:39168030
000292356 0247_ $$2ISSN$$a1748-6815
000292356 0247_ $$2ISSN$$a1878-0539
000292356 037__ $$aDKFZ-2024-01705
000292356 041__ $$aEnglish
000292356 082__ $$a610
000292356 1001_ $$aWill, P. A.$$b0
000292356 245__ $$aTissue-engineered cellulose tubes for microvascular and lymphatic reconstruction: A translational and feasibility study.
000292356 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000292356 3367_ $$2DRIVER$$aarticle
000292356 3367_ $$2DataCite$$aOutput Types/Journal article
000292356 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726234451_17790
000292356 3367_ $$2BibTeX$$aARTICLE
000292356 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292356 3367_ $$00$$2EndNote$$aJournal Article
000292356 500__ $$a2024 Oct;97:200-211
000292356 520__ $$aLymphedema microsurgery is an emerging treatment modality, with dissimilar long-term outcomes. One of the main technical challenges in lymphatic microsurgery is the identification and availability of suitable donor vessels for anastomosis. Tissue engineering using biomaterials has demonstrated promise in addressing vessel quality issues in other fields, but its application in microsurgery is still limited.Decellularized cellulose tubes were developed and bioengineered by decellularizing stems of Taraxacum-Ruderalia. The microscopic structure, mechanical properties, and residual DNA content of the cellulose tubes were evaluated. Human and murine skin fibroblasts and dermal lymphatic endothelial cells were isolated and cultured for recellularization studies. Biocompatibility, proliferative capacity, and ex-vivo endothelialization of the cellulose tubes were assessed as potential interposition grafts. Finally, the engineered cellulose tubes were assessed as interposing xenografts for lymphovenous anastomoses (LVA) in an ex-vivo swine limb model.The decellularized cellulose tubes exhibited a suitable microscopic structure, mechanical properties, and low residual DNA content. The tubes showed adequate biocompatibility, supported cell proliferation, and facilitated spontaneous ex-vivo endothelialization of lymphatic endothelial cells. In the swine limb model, LVA using the engineered cellulose tubes was successfully performed.This translational study presents the use of decellularized cellulose tubes as an adjunct for micro and supermicrosurgical reconstruction. The developed tubes demonstrated favorable structural, mechanical, and biocompatible properties, making them a potential candidate for improving long-term outcomes in lymphedema surgical treatment. The next translational step would be trialing the obtained tubes in a microsurgical in-vivo model.
000292356 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000292356 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292356 650_7 $$2Other$$aAnastomosis, surgical
000292356 650_7 $$2Other$$aCellulose
000292356 650_7 $$2Other$$aHeterografts
000292356 650_7 $$2Other$$aLymphedema
000292356 650_7 $$2Other$$aMicrosurgery
000292356 650_7 $$2Other$$aTissue engineering
000292356 7001_ $$aTaqatqeh, F.$$b1
000292356 7001_ $$0P:(DE-He78)df7cdd0583465c7f2056e3788bfefeec$$aFricke, Fabia$$b2
000292356 7001_ $$aBerner, J. E.$$b3
000292356 7001_ $$aLindenblatt, N.$$b4
000292356 7001_ $$aKneser, U.$$b5
000292356 7001_ $$aHirche, C.$$b6
000292356 773__ $$0PERI:(DE-600)2214150-9$$a10.1016/j.bjps.2024.05.043$$gVol. 97, p. S174868152400305X$$p200-211$$tJournal of plastic, reconstructive & aesthetic surgery$$v97$$x1748-6815$$y2024
000292356 8564_ $$uhttps://inrepo02.dkfz.de/record/292356/files/1-s2.0-S174868152400305X-main.pdf
000292356 8564_ $$uhttps://inrepo02.dkfz.de/record/292356/files/1-s2.0-S174868152400305X-main.pdf?subformat=pdfa$$xpdfa
000292356 909CO $$ooai:inrepo02.dkfz.de:292356$$pVDB
000292356 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)df7cdd0583465c7f2056e3788bfefeec$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000292356 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000292356 9141_ $$y2024
000292356 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000292356 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000292356 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000292356 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000292356 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000292356 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000292356 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000292356 9201_ $$0I:(DE-He78)D470-20160331$$kD470$$lKKE Angewandte Tumorbiologie$$x0
000292356 980__ $$ajournal
000292356 980__ $$aVDB
000292356 980__ $$aI:(DE-He78)D470-20160331
000292356 980__ $$aUNRESTRICTED